These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

762 related items for PubMed ID: 11846299

  • 1. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM.
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3844-51. PubMed ID: 16921036
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E, Jürgens H, Winkler K, Bürger D, Herbst M, Keim M, Bernhard G, Treuner J.
    Cancer; 1992 Nov 15; 70(10):2557-67. PubMed ID: 1482503
    [Abstract] [Full Text] [Related]

  • 6. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
    Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, Pappo AS, Link MP, Grier HE, Wiener ES, Breneman JC, Raney RB, Maurer HM, Donaldson SS.
    J Clin Oncol; 2001 Oct 15; 19(20):4058-64. PubMed ID: 11600608
    [Abstract] [Full Text] [Related]

  • 7. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA, Nascimento AG, Schroeder G, Schomberg PJ, Neglia JP, Sencer SF, Silberman TL, Moertel CL, Tillisch JK, Miser JS.
    Eur J Cancer; 1998 Jul 15; 34(8):1224-9. PubMed ID: 9849484
    [Abstract] [Full Text] [Related]

  • 8. Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: a report of the Intergroup Rhabdomyosarcoma Study.
    Ortega JA, Wharam M, Gehan EA, Ragab AH, Crist W, Webber B, Wiener ES, Haeberlen V, Maurer HM.
    J Clin Oncol; 1991 May 15; 9(5):796-801. PubMed ID: 2016622
    [Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB, Vietti T, Gehan E, Wiener E, Wharam M, Newton WA, Maurer H.
    J Pediatr Hematol Oncol; 1995 Nov 15; 17(4):331-7. PubMed ID: 7583389
    [Abstract] [Full Text] [Related]

  • 10. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM.
    J Clin Oncol; 2000 Jun 15; 18(12):2427-34. PubMed ID: 10856103
    [Abstract] [Full Text] [Related]

  • 11. Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984.
    Raney RB, Crist W, Hays D, Newton W, Ruymann F, Tefft M, Beltangady M.
    Cancer; 1990 Jun 15; 65(12):2787-92. PubMed ID: 2187589
    [Abstract] [Full Text] [Related]

  • 12. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA.
    J Clin Oncol; 2016 Jan 10; 34(2):117-22. PubMed ID: 26503200
    [Abstract] [Full Text] [Related]

  • 13. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma.
    Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS.
    J Pediatr Hematol Oncol; 2001 Jan 10; 23(5):272-6. PubMed ID: 11464981
    [Abstract] [Full Text] [Related]

  • 14. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
    Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, Link M, Donaldson S, Breneman J, Wiener E, Webber B, Maurer H.
    J Pediatr Hematol Oncol; 1997 Jan 10; 19(2):124-9. PubMed ID: 9149741
    [Abstract] [Full Text] [Related]

  • 15. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD, Wiener ES, Qualman SJ, Donaldson SS.
    J Clin Oncol; 1999 Nov 10; 17(11):3468-75. PubMed ID: 10550144
    [Abstract] [Full Text] [Related]

  • 16. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR.
    Pediatr Blood Cancer; 2008 Jan 10; 50(1):33-6. PubMed ID: 17091486
    [Abstract] [Full Text] [Related]

  • 17. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH.
    J Clin Oncol; 2018 Sep 20; 36(27):2770-2777. PubMed ID: 30091945
    [Abstract] [Full Text] [Related]

  • 18. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH.
    J Clin Oncol; 2009 Nov 01; 27(31):5182-8. PubMed ID: 19770373
    [Abstract] [Full Text] [Related]

  • 19. The Intergroup Rhabdomyosarcoma Study-I. A final report.
    Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J.
    Cancer; 1988 Jan 15; 61(2):209-20. PubMed ID: 3275486
    [Abstract] [Full Text] [Related]

  • 20. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
    Ruymann FB, Grovas AC.
    Cancer Invest; 2000 Jan 15; 18(3):223-41. PubMed ID: 10754991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.